{"id":40358,"date":"2025-08-29T14:22:55","date_gmt":"2025-08-29T06:22:55","guid":{"rendered":"https:\/\/flcube.com\/?p=40358"},"modified":"2025-08-29T14:22:55","modified_gmt":"2025-08-29T06:22:55","slug":"everest-medicines-reports-48-yoy-revenue-growth-nefecon-launches-and-velsipity-production-milestone","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40358","title":{"rendered":"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Everest Medicines Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) released unaudited interim financial results for the six months ended 30\u202fJune\u202f2025.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-revenue-amp-profit-highlights\">Revenue &amp; Profit Highlights<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>1H\u202f2025<\/th><th>YoY % Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Revenue<\/strong><\/td><td><strong>RMB\u202f446.1\u202fm<\/strong><\/td><td><strong>+48.0\u202f%<\/strong><\/td><\/tr><tr><td><strong>R&amp;D Expenses<\/strong><\/td><td>RMB\u202f195.2\u202fm<\/td><td><strong>\u201122.1\u202f%<\/strong><\/td><\/tr><tr><td><strong>Net Loss<\/strong><\/td><td>RMB\u202f249.8\u202fm<\/td><td><strong>\u201160.3\u202f%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The 48\u202f% revenue jump was driven by a sustained ramp\u2011up of the company\u2019s three commercialized products: <strong>NEFECON<\/strong> (budesonide for IgA nephropathy), <strong>XERAVA<\/strong> (eravacycline, a novel antibiotic), and <strong>VELSIPITY<\/strong> (etrasimod, an S1P receptor modulator).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-milestones\">Strategic Milestones<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NEFECON<\/strong><\/li>\n\n\n\n<li>Full approval by the China NMPA in May\u202f2025, independent of proteinuria levels.<\/li>\n\n\n\n<li>Official pricing under the 2025 National Reimbursement Drug List (NRDL), expanding access to IgAN patients nationwide.<\/li>\n\n\n\n<li><strong>VELSIPITY<\/strong><\/li>\n\n\n\n<li>Approved in multiple countries and regions.<\/li>\n\n\n\n<li>Localized production launched at Jiashan factory (March\u202f2025).<\/li>\n\n\n\n<li>Investment of RMB\u202f70\u202fm; projected annual capacity of <strong>50\u202fmillion tablets<\/strong> once fully operational.<\/li>\n\n\n\n<li><strong>XERAVA<\/strong><\/li>\n\n\n\n<li>Continued commercial roll\u2011out in key anti\u2011infectives markets.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-r-amp-d-amp-cost-management\">R&amp;D &amp; Cost Management<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Everest reduced R&amp;D spend by <strong>22\u202f%<\/strong> (RMB\u202f195.2\u202fm vs. RMB\u202f253.2\u202fm in 2024H1) by concentrating resources on core pipeline breakthroughs. The disciplined cost structure helped shrink the net loss from RMB\u202f632.4\u202fm to RMB\u202f249.8\u202fm, reflecting stronger product sales and improved operational efficiency.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-outlook\">Outlook<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">With NEFECON\u2019s NRDL entry, VELSIPITY\u2019s robust production pipeline, and XERAVA\u2019s expanding anti\u2011infective footprint, Everest\u202fMedicines is positioned to sustain revenue momentum while continuing to optimise its R&amp;D portfolio for long\u2011term growth.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082900182_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025082900182_c.\"><\/object><a id=\"wp-block-file--media-7f9dfd47-d4d4-4dea-9c2e-9a336c4b0ac0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082900182_c.pdf\">2025082900182_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2025082900182_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7f9dfd47-d4d4-4dea-9c2e-9a336c4b0ac0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines Limited (HKG: 1952) released unaudited interim financial results for the six months ended&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40362,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[30,126,27,1164],"class_list":["post-40358","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-biotech","tag-everest-medicines","tag-finanical-reports","tag-hkg-1952"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hong Kong\u2011listed Everest\u202fMedicines (HKG: 1952) announced unaudited 1H\u202f2025 results: revenue up 48\u202f% to RMB\u202f446.1\u202fm, R&amp;D spend cut 22\u202f%, and net loss slashed to RMB\u202f249.8\u202fm. The company\u2019s commercial portfolio\u2014NEFECON (IgA nephropathy), XERAVA (eravacycline), and VELSIPITY (etrasimod)\u2014continues to expand with NRDL pricing, full NMPA approval, and a 50\u202fm tablet production line in Jiashan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40358\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone\" \/>\n<meta property=\"og:description\" content=\"Hong Kong\u2011listed Everest\u202fMedicines (HKG: 1952) announced unaudited 1H\u202f2025 results: revenue up 48\u202f% to RMB\u202f446.1\u202fm, R&amp;D spend cut 22\u202f%, and net loss slashed to RMB\u202f249.8\u202fm. The company\u2019s commercial portfolio\u2014NEFECON (IgA nephropathy), XERAVA (eravacycline), and VELSIPITY (etrasimod)\u2014continues to expand with NRDL pricing, full NMPA approval, and a 50\u202fm tablet production line in Jiashan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40358\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T06:22:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2905.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone\",\"datePublished\":\"2025-08-29T06:22:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358\"},\"wordCount\":245,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2905.webp\",\"keywords\":[\"Biotech\",\"Everest Medicines\",\"Finanical Reports\",\"HKG: 1952\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40358#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40358\",\"name\":\"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2905.webp\",\"datePublished\":\"2025-08-29T06:22:55+00:00\",\"description\":\"Hong Kong\u2011listed Everest\u202fMedicines (HKG: 1952) announced unaudited 1H\u202f2025 results: revenue up 48\u202f% to RMB\u202f446.1\u202fm, R&D spend cut 22\u202f%, and net loss slashed to RMB\u202f249.8\u202fm. The company\u2019s commercial portfolio\u2014NEFECON (IgA nephropathy), XERAVA (eravacycline), and VELSIPITY (etrasimod)\u2014continues to expand with NRDL pricing, full NMPA approval, and a 50\u202fm tablet production line in Jiashan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40358\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2905.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2905.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40358#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone - Insight, China&#039;s Pharmaceutical Industry","description":"Hong Kong\u2011listed Everest\u202fMedicines (HKG: 1952) announced unaudited 1H\u202f2025 results: revenue up 48\u202f% to RMB\u202f446.1\u202fm, R&D spend cut 22\u202f%, and net loss slashed to RMB\u202f249.8\u202fm. The company\u2019s commercial portfolio\u2014NEFECON (IgA nephropathy), XERAVA (eravacycline), and VELSIPITY (etrasimod)\u2014continues to expand with NRDL pricing, full NMPA approval, and a 50\u202fm tablet production line in Jiashan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40358","og_locale":"en_US","og_type":"article","og_title":"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone","og_description":"Hong Kong\u2011listed Everest\u202fMedicines (HKG: 1952) announced unaudited 1H\u202f2025 results: revenue up 48\u202f% to RMB\u202f446.1\u202fm, R&D spend cut 22\u202f%, and net loss slashed to RMB\u202f249.8\u202fm. The company\u2019s commercial portfolio\u2014NEFECON (IgA nephropathy), XERAVA (eravacycline), and VELSIPITY (etrasimod)\u2014continues to expand with NRDL pricing, full NMPA approval, and a 50\u202fm tablet production line in Jiashan.","og_url":"https:\/\/flcube.com\/?p=40358","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-29T06:22:55+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2905.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40358#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40358"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone","datePublished":"2025-08-29T06:22:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40358"},"wordCount":245,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40358#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2905.webp","keywords":["Biotech","Everest Medicines","Finanical Reports","HKG: 1952"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40358#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40358","url":"https:\/\/flcube.com\/?p=40358","name":"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40358#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40358#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2905.webp","datePublished":"2025-08-29T06:22:55+00:00","description":"Hong Kong\u2011listed Everest\u202fMedicines (HKG: 1952) announced unaudited 1H\u202f2025 results: revenue up 48\u202f% to RMB\u202f446.1\u202fm, R&D spend cut 22\u202f%, and net loss slashed to RMB\u202f249.8\u202fm. The company\u2019s commercial portfolio\u2014NEFECON (IgA nephropathy), XERAVA (eravacycline), and VELSIPITY (etrasimod)\u2014continues to expand with NRDL pricing, full NMPA approval, and a 50\u202fm tablet production line in Jiashan.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40358#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40358"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40358#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2905.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2905.webp","width":1080,"height":608,"caption":"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40358#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest\u202fMedicines Reports 48\u202f% YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2905.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40358","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40358"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40358\/revisions"}],"predecessor-version":[{"id":40363,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40358\/revisions\/40363"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40362"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}